Fluxome Sciences, a Danish biotech company specialising in bio-based production of chemical compounds, has received DKK 100m (USD 21m) in fresh capital from new and existing investors, writes financial daily newspaper Børsen.
The new cash will be used to put a so-called "nutraceutical" on the market containing the chemical compound resveratrol, which is found in red wine and the skins of the grapes from which red wine is made. Scientific studies indicate that resveratrol possesses health-promoting properties that could explain the claimed health benefits associated with drinking moderate quantities of red wine.
Fluxome Sciences' MD Steen Andersen told Børsen: "Research into resveratrol is exploding, and the patent portfolio is growing exponentially." Andersen also draws attention to the fact that GlaxoSmithKline recently acquired Sirtris Pharmaceuticals, whose areas of research include resveratrol and its analogues.
Fluxome Sciences' technology platform involves metabolic engineering that converts microorganisms such as yeast into 'cell factories' that can be designed to produce specific chemical compounds, such as resveratrol, via fermentation. According to the article in Børsen, Fluxome Sciences' method of production can reduce the costs by 50-60% compared with extracting compounds from natural sources.
Fluxome Sciences was founded in 2002 as a spin-out from the Technical University of Denmark. The company is located in Lyngby, north of Copenhagen.